StockUK listing UK0DRPLSEHealthcareBalanced

Biohit Oyj(0DRP) Stock Analysis | Healthcare

EUR --+0.00%
Reward55Moderate
Risk40Moderate
25%Data
Strong 19% profit margin
EUR —+0.00 (+0.00%) Previous close · LSE
Market cap 38.79M
Reward Ratingⓘ55 Moderate reward assessment · 25% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ40 Moderate risk assessment · 50% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0DRP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Biohit Oyj?

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide.

AI Brief Pro

The brief on Biohit Oyj

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Biohit Oyj?

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 38.79M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (55)

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

All Healthcare stocks →
Company Information
IndustryMedical Devices
Beta0.565
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.